<DOC>
	<DOCNO>NCT00263705</DOCNO>
	<brief_summary>Determination guideline regard use adjuvant chemotherapy early breast cancer population Patients 70 year old .</brief_summary>
	<brief_title>Adjuvant Capecitabine Elderly Patients With Breast Cancer : Phase II Study</brief_title>
	<detailed_description>Patients 70 year old represent clinical trial clear guideline regard use adjuvant chemotherapy early breast cancer population . Whether CT retain benefit conferred young patient remain uncertain . Moreover , extensive data regard increase incidence severity side effect , myelotoxicity , mucositis cardiotoxicity , CT population . The efficacy safety CT age patient evaluate different study , haematological malignancy . Clearly , patient ' functional decline age risk CT toxicity rise age . There standard care regard adjuvant chemotherapy breast cancer patient older 70 year old . This pilot study evaluate feasibility safety 6 cycle capecitabine patient age 70 year high-risk early invasive breast cancer undergone optimal surgery . The primary end point evaluate possibility deliver 6 cycle capecitabine dose 1000 mg/m² BID day 1 14 every 3 week , term rate patient receive acceptable relative dose intensity ( RDI ) . Secondary end point safety ( include evaluation possible impact treatment functional , cognitive emotional status patient ) evaluate form geriatric assessment add information classic `` inclusion criterion screen '' term prediction treatment compliance toxicity . The study conduct Jules Bordet Institute . The planned accrual 43 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Women age ³70 year 2 . Histologic diagnosis early breast cancer treat physician considers adjuvant chemotherapy beneficial . Recommended situation example : endocrine non responsive ( ER PgR ) pT &gt; 1 cm , T N+ OR endocrine responsiveness doubtful ( ER and/or PgR poor [ 3 to5 accord Harvey score ( 12 ) £ 30 % positive cell immunohistochemistry ) risk factor ( pT³2 cm N+ G3 Her2/neu positive , etc . ) OR endocrine responsive ( ER PgR &gt; 5 accord Harvey score &gt; 30 % positive cell immunohistochemistry ) least two risk factor ( pT³ 2 cm , N+ , G3 , Her2/neu positive , etc . ) OR Very high risk ( N &gt; 3 ) ER/PgR . 3 . ECOG Performance status £ 1 4 . No previous exposition chemotherapy neoadjuvant set 5 . Adequate organ function include : 1. neutrophil ³ 1.5 x 109 /l 2. platelet ³100 x 109 / l 3. bilirubin &lt; 1.25 x upper normal limit institution 4. transaminase &lt; 2.5 x upper normal limit institution 5. calculated creatinine clearance &gt; 30ml/min ( use Crockoft Gault formula ) 6. absence symptomatic ventricular arrhythmia ; clinically significant Congestive Heart Failure ; clinical and/or ECG evidence myocardial infarction within last 12 month ; Coronary artery disease require medication . 6 . Absence psychological , familial sociological condition comorbidities may affect compliance 7 . Written inform consent obtain accord local ethic committee guideline</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>